| A phase 3 trial of bevacizumab in ovarian cancer TJ Perren, AM Swart, J Pfisterer, JA Ledermann, E Pujade-Lauraine, ... New England Journal of Medicine 365 (26), 2484-2496, 2011 | 2545 | 2011 |
| Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients B Aktas, M Tewes, T Fehm, S Hauch, R Kimmig, S Kasimir-Bauer Breast cancer research 11, 1-9, 2009 | 888 | 2009 |
| Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the … J Pfisterer, M Plante, I Vergote, A du Bois, H Hirte, AJ Lacave, U Wagner, ... Journal of Clinical Oncology 24 (29), 4699-4707, 2006 | 861 | 2006 |
| A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms P Harter, J Sehouli, D Lorusso, A Reuss, I Vergote, C Marth, JW Kim, ... New England Journal of Medicine 380 (9), 822-832, 2019 | 498 | 2019 |
| Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome S Hahn, OE Janssen, S Tan, K Pleger, K Mann, M Schedlowski, R Kimmig, ... European journal of endocrinology 153 (6), 853-860, 2005 | 490 | 2005 |
| Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome S Hahn, U Haselhorst, S Tan, B Quadbeck, M Schmidt, S Roesler, ... Experimental and clinical endocrinology & diabetes 114 (10), 577-583, 2006 | 446 | 2006 |
| Incorporation of pazopanib in maintenance therapy of ovarian cancer A Du Bois, A Floquet, JW Kim, J Rau, JM Del Campo, M Friedlander, ... Journal of clinical oncology 32 (30), 3374-3382, 2014 | 381 | 2014 |
| Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells S Kasimir-Bauer, O Hoffmann, D Wallwiener, R Kimmig, T Fehm Breast Cancer Research 14, 1-9, 2012 | 364 | 2012 |
| MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors K Brischwein, B Schlereth, B Guller, C Steiger, A Wolf, R Lutterbuese, ... Molecular immunology 43 (8), 1129-1143, 2006 | 316 | 2006 |
| Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer I Jochmus-Kudielka, A Schneider, R Braun, R Kimmig, U Koldovsky, ... JNCI: Journal of the National Cancer Institute 81 (22), 1698-1704, 1989 | 310 | 1989 |
| Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells T Fehm, O Hoffmann, B Aktas, S Becker, EF Solomayer, D Wallwiener, ... Breast Cancer Research 11, 1-9, 2009 | 307 | 2009 |
| Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM× anti-CD3 antibody: a phase I/II study A Burges, P Wimberger, C Kümper, V Gorbounova, H Sommer, ... Clinical Cancer Research 13 (13), 3899-3905, 2007 | 301 | 2007 |
| Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies M Tewes, B Aktas, A Welt, S Mueller, S Hauch, R Kimmig, ... Breast cancer research and treatment 115, 581-590, 2009 | 277 | 2009 |
| Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the … J Pfisterer, B Weber, A Reuss, R Kimmig, A Du Bois, U Wagner, ... Journal of the National Cancer Institute 98 (15), 1036-1045, 2006 | 262 | 2006 |
| Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the … P Wimberger, N Lehmann, R Kimmig, A Burges, W Meier, A Du Bois Gynecologic oncology 106 (1), 69-74, 2007 | 234 | 2007 |
| Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup … A du Bois, B Weber, J Rochon, W Meier, A Goupil, S Olbricht, JC Barats, ... Journal of clinical oncology 24 (7), 1127-1135, 2006 | 233 | 2006 |
| Determinants of emotional distress in women with polycystic ovary syndrome S Elsenbruch, S Benson, S Hahn, S Tan, K Mann, K Pleger, R Kimmig, ... Human Reproduction 21 (4), 1092-1099, 2006 | 194 | 2006 |
| Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische … P Wimberger, M Wehling, N Lehmann, R Kimmig, B Schmalfeldt, ... Annals of surgical oncology 17, 1642-1648, 2010 | 193 | 2010 |
| Cancer in pregnancy: maternal-fetal conflict FS Oduncu, R Kimmig, H Hepp, B Emmerich Journal of cancer research and clinical oncology 129, 133-146, 2003 | 193 | 2003 |
| Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate J Engel, R Eckel, G Schubert-Fritschle, J Kerr, W Kuhn, J Diebold, ... European Journal of Cancer 38 (18), 2435-2445, 2002 | 192 | 2002 |
